UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 133

Sortiert nach

Assessment of disease activity in rheumatoid arthritis using a novel folate targeted radiopharmaceutical Folatescan

Clinical and experimental rheumatology, 2009-03, Vol.27 (2), p.253

2009

Volltextzugriff (PDF)

CTC-based biomarkers & PSMA-targeted imaging in patients with metastatic castrate-resistant prostate cancer (mCRPC)

Annals of oncology, 2018-10, Vol.29, p.viii294-viii294

2018

Volltextzugriff (PDF)

Phase I Trial of 72-Hour Continuous Infusion UCN-01 in Patients With Refractory Neoplasms

Journal of clinical oncology, 2001-04, Vol.19 (8), p.2319-2333

2001

Volltextzugriff (PDF)

620 A Study of PNT2258 (DNA-targeted Blocker of BCL2 Expression) in Patients with Advanced Solid Tumors

European journal of cancer (1990), 2012-11, Vol.48, p.191-191

2012

Volltextzugriff (PDF)

A Phase I Study of Combination Therapy with Immunotoxins IgG-HD37-Deglycosylated Ricin A Chain (dgA) and IgG-RFB4-dgA (Combotox) in Patients with Refractory CD19(+), CD22(+) B Cell Lymphoma

Clinical cancer research, 2000-04, Vol.6 (4), p.1302-1313

2000

Volltextzugriff (PDF)

P-23 Phase II study (daNIS-3) of the anti–TGF-β monoclonal antibody NIS793 and other new investigational drug combinations with standard-of-care therapy vs standard-of-care alone in patients with second-line metastatic colorectal cancer

Annals of oncology, 2022-06, Vol.33, p.S254-S255

2022

Volltextzugriff (PDF)

OP 93 The co-development of a folate receptor molecular diagnostic imaging agent (99mTc-EC20) and folate receptor targeted drug conjugate (EC145) in the treatment of ovarian cancer patients

European journal of cancer (1990), 2011, Vol.47, p.S8-S8

2011

Volltextzugriff (PDF)

Lugano 2014 criteria for assessing FDG-PET/CT in lymphoma: an operational approach for clinical trials

Drug design, development and therapy, 2017-01, Vol.11, p.1719-1728

2017

Volltextzugriff (PDF)

Phase 1 study of the PSMA-targeted small-molecule drug conjugate EC1169 in patients with metastatic castrate-resistant prostate cancer (mCRPC)

Annals of oncology, 2017-09, Vol.28, p.v273-v273

2017

Volltextzugriff (PDF)

Phase I Clinical and Pharmacokinetic Study of Flavopiridol Administered as a Daily 1-Hour Infusion in Patients With Advanced Neoplasms

Journal of clinical oncology, 2002-10, Vol.20 (19), p.4074-4082

2002

Volltextzugriff (PDF)

Use of 99mTc-EC20 (a folate-targeted imaging agent) to predict response to therapy with EC145 (folate-targeted therapy) in advanced ovarian cancer

Journal of clinical oncology, 2010-05, Vol.28 (15_suppl), p.5034-5034

2010

Volltextzugriff (PDF)

PRECEDENT: A randomized phase II trial comparing EC145 and pegylated liposomal doxorubicin (PLD) in combination, versus PLD alone, in subjects with platinum-resistant ovarian cancer

Journal of clinical oncology, 2010-06, Vol.28 (18_suppl), p.LBA5012b-LBA5012b

2010

Volltextzugriff (PDF)

A phase I study of the folate-targeted conjugate EC0489 in patients with refractory or advanced metastatic cancer

Journal of clinical oncology, 2010-05, Vol.28 (15_suppl), p.3088-3088

2010

Volltextzugriff (PDF)

A phase I study of EC0225 administered weeks 1 and 2 of a 4-week cycle

Journal of clinical oncology, 2010-05, Vol.28 (15_suppl), p.3082-3082

2010

Volltextzugriff (PDF)

PRECEDENT: A randomized phase II trial comparing EC145 and pegylated liposomal doxorubicin (PLD) in combination, versus PLD alone, in subjects with platinum-resistant ovarian cancer

Journal of clinical oncology, 2011-05, Vol.29 (15_suppl), p.5045-5045

2011

Volltextzugriff (PDF)

A phase I study of EC145 administered weeks 1 and 3 of a 4-week cycle in patients with refractory solid tumors

Journal of clinical oncology, 2007-06, Vol.25 (18_suppl), p.2577-2577

2007

Volltextzugriff (PDF)

Phase I trial of EC90 (keyhole-limpet hemocyanin fluorescein isothiocyanate conjugate) with GPI-0100 adjuvant followed by EC17 (Folate-Fluorescein Isothiocyanate Conjugate) in Patients (pts) with metastatic renal cell carcinoma (MRCC)

Journal of clinical oncology, 2005-06, Vol.23 (16_suppl), p.2590-2590

2005

Volltextzugriff (PDF)

The Toxicity of Deglycosylated Ricin A Chain-containing Immunotoxins in Patients with Non-Hodgkin’s Lymphoma Is Exacerbated by Prior Radiotherapy: A Retrospective Analysis of Patients in Five Clinical Trials

Clinical cancer research, 2001-02, Vol.7 (2), p.255-258

2001

Volltextzugriff (PDF)

A phase II study of FolateImmune (EC90 with GP1–0100 adjuvant followed by EC17) with low dose cytokines interleukin-2 (IL-2) and interferon-α (IFN-α) in patients with refractory or metastatic cancer

Journal of clinical oncology, 2007-06, Vol.25 (18_suppl), p.13516-13516

2007

Volltextzugriff (PDF)

842PCTC-based biomarkers & PSMA-targeted imaging in patients with metastatic castrate-resistant prostate cancer (mCRPC)

Annals of oncology, 2018-10, Vol.29 (suppl_8)

2018

Volltextzugriff (PDF)

Quantitative determination of perifosine, a novel alkylphosphocholine anticancer agent, in human plasma by reversed-phase liquid chromatography–electrospray mass spectrometry

Journal of chromatography. B, Biomedical sciences and applications, 2001-08, Vol.759 (2), p.247-257

2001

Volltextzugriff (PDF)

Flavopiridol-related Proinflammatory Syndrome Is Associated with Induction of Interleukin-6

Clinical cancer research, 2003-02, Vol.9 (2), p.562-570

2003

Volltextzugriff (PDF)

Clinical pharmacology and pharmacogenetics of flavopiridol 1-h i.v. infusion in patients with refractory neoplasms

Anti-cancer drugs, 2003-02, Vol.14 (2), p.125-135

2003

Volltextzugriff (PDF)

Mechanical Properties of Sickle Cell Membranes

Blood, 1990-04, Vol.75 (8), p.1711-1717

1990

Volltextzugriff (PDF)

Mechanical properties of sickle cell membranes

Blood, 1990-04, Vol.75 (8), p.1711-1717

1990

Volltextzugriff (PDF)

1 – 25 von 133

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(106)
Mit Volltextzugriff
(104)

Publikationsform

Sprache

Erscheinungsjahr

n.n

Thema

Science & Technology
(58)
Humans
(56)
Life Sciences & Biomedicine
(56)
Male
(35)
Female
(33)
Middle Aged
(32)
Biological And Medical Sciences
(29)
Medical Sciences
(29)
Aged
(23)
Adult
(22)
Oncology
(20)
Gastroenterology & Hepatology
(19)
Tumors
(11)
Dose-Response Relationship, Drug
(10)
Treatment Outcome
(10)
Gastroenterology. Liver. Pancreas. Abdomen
(9)
Pharmacology. Drug Treatments
(8)
Surgery
(8)
Adenocarcinoma - Pathology
(7)
Aged, 80 And Over
(7)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Assessment of disease activity in rheumatoid arthritis using a novel folate targeted radiopharmaceutical Folatescan

CTC-based biomarkers & PSMA-targeted imaging in patients with metastatic castrate-resistant prostate cancer (mCRPC)

Phase I Trial of 72-Hour Continuous Infusion UCN-01 in Patients With Refractory Neoplasms

620 A Study of PNT2258 (DNA-targeted Blocker of BCL2 Expression) in Patients with Advanced Solid Tumors

A Phase I Study of Combination Therapy with Immunotoxins IgG-HD37-Deglycosylated Ricin A Chain (dgA) and IgG-RFB4-dgA (Combotox) in Patients with Refractory CD19(+), CD22(+) B Cell Lymphoma

P-23 Phase II study (daNIS-3) of the anti–TGF-β monoclonal antibody NIS793 and other new investigational drug combinations with standard-of-care therapy vs standard-of-care alone in patients with second-line metastatic colorectal cancer

OP 93 The co-development of a folate receptor molecular diagnostic imaging agent (99mTc-EC20) and folate receptor targeted drug conjugate (EC145) in the treatment of ovarian cancer patients

Lugano 2014 criteria for assessing FDG-PET/CT in lymphoma: an operational approach for clinical trials

Phase 1 study of the PSMA-targeted small-molecule drug conjugate EC1169 in patients with metastatic castrate-resistant prostate cancer (mCRPC)

Phase I Clinical and Pharmacokinetic Study of Flavopiridol Administered as a Daily 1-Hour Infusion in Patients With Advanced Neoplasms

Use of 99mTc-EC20 (a folate-targeted imaging agent) to predict response to therapy with EC145 (folate-targeted therapy) in advanced ovarian cancer

PRECEDENT: A randomized phase II trial comparing EC145 and pegylated liposomal doxorubicin (PLD) in combination, versus PLD alone, in subjects with platinum-resistant ovarian cancer

A phase I study of the folate-targeted conjugate EC0489 in patients with refractory or advanced metastatic cancer

A phase I study of EC0225 administered weeks 1 and 2 of a 4-week cycle

PRECEDENT: A randomized phase II trial comparing EC145 and pegylated liposomal doxorubicin (PLD) in combination, versus PLD alone, in subjects with platinum-resistant ovarian cancer

A phase I study of EC145 administered weeks 1 and 3 of a 4-week cycle in patients with refractory solid tumors

Phase I trial of EC90 (keyhole-limpet hemocyanin fluorescein isothiocyanate conjugate) with GPI-0100 adjuvant followed by EC17 (Folate-Fluorescein Isothiocyanate Conjugate) in Patients (pts) with metastatic renal cell carcinoma (MRCC)

The Toxicity of Deglycosylated Ricin A Chain-containing Immunotoxins in Patients with Non-Hodgkin’s Lymphoma Is Exacerbated by Prior Radiotherapy: A Retrospective Analysis of Patients in Five Clinical Trials

A phase II study of FolateImmune (EC90 with GP1–0100 adjuvant followed by EC17) with low dose cytokines interleukin-2 (IL-2) and interferon-α (IFN-α) in patients with refractory or metastatic cancer

842PCTC-based biomarkers & PSMA-targeted imaging in patients with metastatic castrate-resistant prostate cancer (mCRPC)

Quantitative determination of perifosine, a novel alkylphosphocholine anticancer agent, in human plasma by reversed-phase liquid chromatography–electrospray mass spectrometry

Flavopiridol-related Proinflammatory Syndrome Is Associated with Induction of Interleukin-6

Clinical pharmacology and pharmacogenetics of flavopiridol 1-h i.v. infusion in patients with refractory neoplasms

Mechanical Properties of Sickle Cell Membranes

Mechanical properties of sickle cell membranes

Suchergebnisse filtern